Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

The ABODE Study for Patients Undergoing Neoadjuvant Chemotherapy (ABODE NAC)

15 novembre 2026 mis à jour par: University Health Network, Toronto

At-home Breast Oncology Care Delivered With E-health Solutions - The ABODE Study for Patients Undergoing Neoadjuvant Chemotherapy

Over 12,000 women in Ontario will be diagnosed with BC this year. The COVID-19 pandemic changed the healthcare system, making it important to have high-quality virtual (online) care. Mobile health, which means getting health services on your phone, has become a common part of healthcare.

A previously developed app will be used in this study to improve the virtual care experience for BC patients that will be undergoing neoadjuvant chemotherapy. With this app, patients can:

  • Get personalized resources that can help them navigate through the stages of their treatment.
  • Access vetted information about their cancer & treatment from a health library.
  • Receive surveys about their health and well-being.
  • Get mental and social support from an e-coach, who are volunteers trained to help and support patients. The e-coaches will provide information, listen to how participants are feeling, and help participants find information they might need.
  • Connect with a physiotherapist to discuss healthy living and wellness.

Participants will be randomly put into one of two groups: one group will use the app, while the other will continue to get usual care without the app. Participants will have access to the app for 12 months. They will be asked about their experience, how they are feeling, and their health status at several timepoints.

At the end of the study, the two groups will be compared to see how active and engaged participants are in their treatment and see how this changes over 12 months. The study team will also examine how participants are feeling emotionally and their overall quality of life. Health service utilization data and chart review will be used to examine how patients used health services over the course of their treatment. Qualitative interviews will be conducted for some patients about their treatment and experience on the app, using photos that they submit throughout the study.

Aperçu de l'étude

Statut

Pas encore de recrutement

Les conditions

Intervention / Traitement

Type d'étude

Interventionnel

Inscription (Estimé)

200

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

  • Nom: Tulin Cil
  • Numéro de téléphone: 3984 416-946-4507
  • E-mail: tulin.cil@uhn.ca

Sauvegarde des contacts de l'étude

Lieux d'étude

    • Ontario
      • Toronto, Ontario, Canada, M5G2M9
        • University Health Network
        • Contact:
          • Tulin Cil, MD, MEd
          • Numéro de téléphone: 4169464507
          • E-mail: tulin.cil@uhn.ca

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Femelle

La description

Inclusion Criteria:

  • Females (assigned female at birth)*
  • Diagnosed with primary invasive BC and receiving curative intent treatment
  • Must have neoadjuvant chemotherapy as their first step in treatment
  • Receiving systemic therapy at UHN
  • Age≥18
  • Access to an electronic device with connection to the internet
  • A valid email address
  • Can communicate in English

Exclusion Criteria:

  • Males (assigned male at birth), as BC surgical treatment options and experiences are different
  • Diagnosed with non-operable breast cancer
  • Stage 4/metastatic (whether determined at diagnosis or during surgery)
  • Those with hearing or visual challenges
  • Should not be enrolled in any other UHN study using an e-Health application

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Aucune intervention: Control

Standard care

Expérimental: Intervention (App)

App + standard care

The app is a customized version of an eHealth platform that is already in use in other disease sites at UHN. The app has been approved by UHN as a secure communication method. We have customized the app to function within breast cancer care pathways.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Patient Activation Measure 13 (PAM-13)
Délai: Baseline 3 months post-baseline 3 months post-op 12 months post-baseline

A 13-item scale measuring self-reported knowledge, skills and confidence for self-management of one's health and healthcare. Items are rated on a 4-point Likert scale (1 = strongly disagree, 2 = disagree, 3 = agree, 4 = strongly agree). Higher scores indicate a greater patient activation.

Baseline 3 months post-baseline 3 months post-op 12 months post-baseline

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Impact of Events Scale - Revised (IES-R)
Délai: Baseline 3 months post-baseline 3 months post-op 12 months post-baseline

A 22-item scale measuring subjective distress as it relates to a specific event, based on intrusion and avoidance. Items are rated on a 5-point scale ranging from 0 ("not at all") to 4 ("extremely"). The IES-R yields a total score (ranging from 0 to 88); higher scores mean worse symptoms.

Baseline 3 months post-baseline 3 months post-op 12 months post-baseline
Generalized Anxiety Disorder 7 (GAD-7)
Délai: Baseline 3 months post-baseline 3 months post-op 12 months post-baseline

A 7-item measure of generalized anxiety disorder based on symptoms. The GAD-7 is scored by adding its seven items (each 0-3), producing a total from 0-21. Higher scores indicate higher anxiety.

Baseline 3 months post-baseline 3 months post-op 12 months post-baseline
European Organisation for Research and Treatment of Cancer - Quality of Life Questionnaire: EORTC QLQ-C30
Délai: Baseline 3 months post-baseline 3 months post-op 12 months post-baseline

A 30-item survey assessing of quality of life in cancer patients. The EORTC Core Questionnaire (QLQ-C30) includes six clearly distinguishable functioning scales that have been thoroughly tested and validated. Raw item averages are transformed into a 0-100 scale, where higher scores indicate better functioning (for function/global scales) or worse symptoms (for symptom scales).

Baseline 3 months post-baseline 3 months post-op 12 months post-baseline
European Organisation for Research and Treatment of Cancer - Quality of Life Questionnaire Information Module (EORTC-INFO25)
Délai: 9 months post-baseline

A 25-item survey to measure the amount of medical information received throughout treatment. This scale uses a 4-point Likert scale (1 'Not at All' to 4 'Very Much'). Scores average and transformed to 0-100 scale. High score for functional scale indicate higher satisfaction with provided treatment information.

9 months post-baseline
European Organisation for Research and Treatment of Cancer - Breast Cancer-Specific Quality of Life Questionnaire (EORTC QLQ-BR42)
Délai: Baseline 3 months post-baseline 3 months post-op 12 months post-baseline

A 42-item survey assessing quality of life specifically for breast cancer patients.

The survey includes functional scales (body image, sexual functioning, sexual enjoyment, and future perspective) and single item symptoms scales (systemic therapy side effects, breast symptoms, arm symptoms, and upset by hair loss). Questions used 4-point Likert scale (1 'Not at All' to 4 'Very Much'). Scores average and transformed to 0-100 scale. A high score for functional scale indicate a high/healthy level of functioning while a high score for single item indicate a high level of symptomatology/problems.

Baseline 3 months post-baseline 3 months post-op 12 months post-baseline
Health Education Impact Questionnaire (heiQ)
Délai: Baseline 9 months post-baseline

A 40-item scale measuring the intended outcomes of health education and self-management programs. heiQ is a validated, self-reported instrument with 8 domains to comprehensively evaluate patient education program and self-management intervention. Each domain score ranges from 1 to 4; a higher score indicates better outcome.

Baseline 9 months post-baseline
Clinical Evaluation Questionnaire -INS (CEQ-INS)
Délai: 9 months post-baseline

A 19-item scale evaluation of patient's experience of cancer care in terms of their receipt of useful and relevant information about cancer, assistance with service navigation, and support from their care team. CEQ-INS is a self-reported instrument with questions used 4-point Likert scale (1 'Not at All' to 4 'Very Much'). Higher scores correlate with higher patient satisfaction with the information and support provided from their care team.

9 months post-baseline
Health Service Outcomes - Wait Times
Délai: Until 15 months post-baseline

The length of time from referral to procedure or discharge, as recorded in the Wait Times Information System (TIS), which tracks wait times for surgeries, diagnostic imaging (e.g., MRI, CT), and alternate level of care (ALC) in Ontario hospitals.

Until 15 months post-baseline
Health Service Outcomes - Ambulatory Clinical Activity
Délai: Until 15 months post-baseline

Ambulatory clinical activity will be collected from the National Ambulatory Care Reporting System (NACRS).

Until 15 months post-baseline
Health Service Outcomes - Discharge Information
Délai: Until 15 months post-baseline

Discharge information will be collected from the Discharge Abstracting Database (DAD) and used to understand discharge and patient recovery.

Until 15 months post-baseline

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

1 novembre 2026

Achèvement primaire (Estimé)

1 octobre 2028

Achèvement de l'étude (Estimé)

1 octobre 2028

Dates d'inscription aux études

Première soumission

28 octobre 2026

Première soumission répondant aux critères de contrôle qualité

15 novembre 2026

Première publication (Réel)

20 novembre 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

20 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

15 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • 24-5369

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .